Trevi Therapeutics (TRVI) Misses Q1 EPS by 2c
Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.